Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that unavoidable routine of meetings, deadlines, and the like has predictably returned. But look on the bright side: At least you are not like Martin Shkreli, who is awaiting trial for securities fraud. With this in mind, the time has come to quaff a cup of stimulation and peruse the tidbits. So here you go. Have a great day …

Jury selection begins on Monday in the federal securities-fraud trial of Martin Shkreli, who remains a symbol of pharmaceutical greed for jacking up drug prices, The Wall Street Journal reminds us. Federal prosecutors allege that Shkreli committed fraud, misled investors in his hedge fund, and looted Retrophin, a publicly traded drug maker to cover the losses when those funds foundered. “I’m excited,” he told the Associated Press. “I can’t wait.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.